Selvedge Venture
VC Fund
London, United Kingdom
Selvedge Venture is a VC fund in London focused on Biotechnology and Health Care. Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Selvedge Venture invests in
BiotechnologyHealth CareMedicalLife ScienceBiopharma
Stages Selvedge Venture invests in
SeedSeries APre-SeedVenture - Series UnknownFunding Round
Countries Selvedge Venture invests in
United KingdomUnited StatesCanadaGermanySingapore
Round sizes
Seed $1.4M–$9.6MPre-Seed $1.1M–$2.5MSeries A $3.5M–$30M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.4M–$9.6M
- Pre-Seed
- $1.1M–$2.5M
- Series A
- $3.5M–$30M
Investment Focus
Industry
- Biotechnology 8 (40%)
- Health Care 7 (35%)
- Medical 4 (20%)
- Life Science 4 (20%)
- Biopharma 2 (10%)
Stage
- Seed 5 (25%)
- Series A 5 (25%)
- Pre-Seed 3 (15%)
- Venture - Series Unknown 3 (15%)
- Funding Round 1 (5%)
Country
- United Kingdom 7 (35%)
- United States 2 (10%)
- Canada 1 (5%)
- Germany 1 (5%)
- Singapore 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alasdair Thong
Founding Partner
|
Founding Partner | Total investments: 8 | Find email | |
Angelos Spiliopoulos
Business Analyst
|
Business Analyst | Total investments: 0 | Find email | |
Esra Berkol
Head of Investor Relations
|
Head of Investor Relations | Total investments: 0 | Find email | |
Robert Thong
Venture Development Partner
|
Venture Development Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks. | $3.5M / Series A / Oct 12, 2023 | ||
| BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | Jun 22, 2023 | ||
| BIOS Health uses data-driven insights from the nervous system to build neural digital therapies - the next big trend in precision medicines. The human nervous system carries vast quantities of data, and BIOS’ ability to precisely link nerve activity to specific conditions through the discovery of their neural biomarkers is a game changer forprecision medicine. BIOS’ research could hold the key to new treatments for conditions including hypertension, diabetes, rheumatoid arthritis, and even diseases of the brain itself such as Parkinson’s or Alzheimer’s. BIOS is positioned to provide the neural code on which a new generation of treatments can be built that can enable millions of people suffering from chronic diseases to improve their quality of life.Co-founded by Cambridge University researchers Emil Hewage, a computational neuroscientist, and Oliver Armitage, a biomechanical engineer, BIOS is made up of a wide range of experts from neuroscience, machine learning, software engineering, applied biomaterials, biotechnology and medicine. Advisors include Oxford University Professors David Paterson and Tim Denison, CEO of Candel Therapeutics Paul Peter Tak, and IQVIA VP of Genomic and Precision Medicine Joanne Hackett (Chair of the BIOS Board). | $20M / Series A / Jun 22, 2023 | ||
| Operator of a precision medicine business intended to develop and commercialize data assets for metabolic syndrome. The company applies computational systems' biology, also combines data science and biology expertise to offer data-driven development of therapeutics, along with develops machine learning-enhanced systems biology models andcomposite biomarkers, enabling diagnostic companies to get access to new therapeutic and diagnostic R&D programmes for subsequent co-development and global commercialization with multinational biopharma. | $6.2M / Seed / May 04, 2023 | ||
| Ochre Bio develops genomic medicines to rejuvenate donors' livers before transplant, so that everyone who needs a new liver gets one. They use genomics to find and shut down over-active genes driving disease and then go directly to testing therapies in discarded donor livers that keep alive outside of the body.Ochre Bio is within the heartof Oxford’s biotech innovation hub. Their scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market. | $30M / Series A / Oct 10, 2022 | ||
| Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost. | $2M / Pre-Seed / Apr 25, 2022 | ||
| Oxford Medical Products is developing a safe, effective and affordable breakthrough technology for weight loss that uses a self-expanding capsule which occupies space in the stomach, reducing hunger and leading to significant weight loss. Led by a team of scientists, medical professionals, and entrepreneurs who have come together to solve one ofthe world’s toughest and most urgent medical challenges. | $3.3M / Venture - Series Unknown / Mar 09, 2022 | ||
| Operator of a precision medicine business intended to develop and commercialize data assets for metabolic syndrome. The company applies computational systems' biology, also combines data science and biology expertise to offer data-driven development of therapeutics, along with develops machine learning-enhanced systems biology models andcomposite biomarkers, enabling diagnostic companies to get access to new therapeutic and diagnostic R&D programmes for subsequent co-development and global commercialization with multinational biopharma. | $1.4M / Seed / Feb 07, 2022 | ||
| Kytopen develops genome engineering platforms that enable cell therapy research and manufacturing. The company provides non-viral gene delivery systems that facilitate the delivery of mRNA, DNA, and CRISPR Cas9 RNP into cells while retaining cell functionality. Its Flowfect® technology allows high-throughput transfections and scalable optimizationfrom small experiments to large-scale manufacturing.Kytopen’s platforms include Flowfect Discover™ for automated small-volume screening and Flowfect TX® for large-scale delivery, supporting drug discovery and process development. The systems integrate electrical, mechanical, and chemical forces to fine-tune gene delivery, enabling controlled and predictable scaling. The company’s solutions focus on removing bottlenecks in gene delivery and streamlining the transition from laboratory research to therapeutic production. | $30M / Series A / Sep 28, 2021 | ||
| Sanome are combining different types of biomarkers to develop engaging, useful and accurate diagnostic products (IVDs) that enable early detection and prevention of disease. The IVD innovation engine, will ultimately enable new approaches for healthcare delivery, providing access to novel at-home testing paradigms for all people. | $2.5M / Pre-Seed / Sep 28, 2021 | ||
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,825 investors
Biotech Investors
24,243 investors
Biotechnology Investors
21,493 investors
Medical Investors
21,329 investors
Life Science Investors
7,571 investors
Health Care VC Funds
36,610 investors
Biotech VC Funds
20,947 investors
Biotechnology VC Funds
18,846 investors
Medical VC Funds
18,339 investors
FAQ
What does Selvedge Venture invest in?
Selvedge Venture invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 20 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Selvedge Venture invest in?
Selvedge Venture typically joins rounds of $1.4M–$9.6M at Seed, $1.1M–$2.5M at Pre-Seed and $3.5M–$30M at Series A. These are whole funding-round sizes, not Selvedge Venture's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Selvedge Venture took part in.
How do I contact Selvedge Venture?
Public channels for Selvedge Venture include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Selvedge Venture?
The team at Selvedge Venture includes Alasdair Thong (Founding Partner), Angelos Spiliopoulos (Business Analyst) and Esra Berkol (Head of Investor Relations). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
